Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: KDN018
MIFTS: 68

Kidney Disease

Categories: Blood diseases, Bone diseases, Genetic diseases, Nephrological diseases
Genes Variations Tissues Related diseases Publications Pathways Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Kidney Disease

About this section

MalaCards integrated aliases for Kidney Disease:

Name: Kidney Disease 12 3 15
Nephropathy 12 76 29 6 15
Kidney Diseases 43 44 73
Renal Failure 76 55 40
Abnormality of the Kidney 29 6
Kidney Failure 43 73
Renal Failure Adverse Event 73
Abnormal Renal Function 73
Kidney Dysfunction 55
Renal Anomaly 55
Renal Disease 55

Classifications:

MalaCards categories:
Global: Genetic diseases
Anatomical: Nephrological diseases Blood diseases Bone diseases
See all MalaCards categories (disease lists)
ICD10: 33


External Ids:

Disease Ontology 12 DOID:557
MeSH 44 D007674
NCIt 50 C3149 C34843
SNOMED-CT 68 90708001
Sources

Summaries for Kidney Disease

About this section
MedlinePlus : 43 Healthy kidneys clean your blood by removing excess fluid, minerals, and wastes. They also make hormones that keep your bones strong and your blood healthy. But if the kidneys are damaged, they don't work properly. Harmful wastes can build up in your body. Your blood pressure may rise. Your body may retain excess fluid and not make enough red blood cells. This is called kidney failure. If your kidneys fail, you need treatment to replace the work they normally do. The treatment options are dialysis or a kidney transplant. Each treatment has benefits and drawbacks. No matter which treatment you choose, you'll need to make some changes in your life, including how you eat and plan your activities. But with the help of health care providers, family, and friends, most people with kidney failure can lead full and active lives. NIH: National Institute of Diabetes and Digestive and Kidney Diseases

MalaCards based summary : Kidney Disease, also known as nephropathy, is related to polycystic kidney disease 1 with or without polycystic liver disease and polycystic kidney disease 4 with or without polycystic liver disease, and has symptoms including polyuria An important gene associated with Kidney Disease is COL4A5 (Collagen Type IV Alpha 5 Chain), and among its related pathways/superpathways is A-beta Pathways: Plaque Formation and APP Metabolism. The drugs Perindopril and Valsartan have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and endothelial, and related phenotypes are cardiovascular system and digestive/alimentary

Disease Ontology : 12 A urinary system disease that is located in the kidney.

Wikipedia : 76 Kidney disease, or renal disease, also known as nephropathy, is damage to or disease of a kidney.... more...

Sources

Related Diseases for Kidney Disease

About this section

Diseases in the Kidney Disease family:

Acute Kidney Failure Chronic Kidney Failure
Renal Infectious Disease Ren-Related Kidney Disease

Diseases related to Kidney Disease via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1903)
# Related Disease Score Top Affiliating Genes
1 polycystic kidney disease 1 with or without polycystic liver disease 34.6 PKD1 PKD2 PKD2L1 PKHD1
2 polycystic kidney disease 4 with or without polycystic liver disease 34.5 PKD1 PKD2 PKHD1 TMEM67
3 autosomal dominant polycystic kidney disease 34.5 ACE ALB CST3 PKD1 PKD2 PKD2L1
4 polycystic kidney disease 34.4 ACE PKD1 PKD1L1 PKD1L2 PKD2 PKD2L1
5 polycystic kidney disease 2 with or without polycystic liver disease 34.4 PKD1 PKD1L1 PKD2 PKD2L1 PKD2L2 PKDREJ
6 cystic kidney disease 34.3 ALB PKD1 PKD2 PKD2L1 PKHD1 TMEM67
7 chronic kidney failure 34.1 ACE ALB COL4A5 CST3 PKD1 PKD2
8 polycystic kidney disease 3 with or without polycystic liver disease 33.8 PKD1 PKD2
9 alport syndrome and thin basement membrane nephropathy 33.5 COL4A4 COL4A5
10 nephronophthisis 33.4 CEP290 PKD1 PKD2 PKHD1 TMEM67 UMOD
11 hematuria, benign familial 33.1 COL4A4 COL4A5
12 end stage renal failure 33.1 ACE ALB COL4A5 CST3 PKD1 UMOD
13 polycystic liver disease 32.4 ALB PKD1 PKD2 PKHD1
14 caroli disease 32.3 PKD1 PKHD1
15 glomerulonephritis 32.2 ALB COL4A4 COL4A5
16 polycystic liver disease 1 with or without kidney cysts 32.2 PKD1 PKD2 PKHD1 UMOD
17 multicystic dysplastic kidney 31.5 PKD1 PKD2
18 nephronophthisis 19 31.3 TMEM67 UMOD
19 joubert syndrome 6 31.3 CEP290 TMEM67
20 liver disease 31.0 ALB PKD1 PKD2 PKHD1
21 congenital hepatic fibrosis 30.8 PKD1 PKHD1 TMEM67
22 renal dysplasia, cystic 30.7 CEP290 PKD1
23 pyelonephritis 30.5 ACE ALB UMOD
24 focal segmental glomerulosclerosis 30.4 ACE ALB COL4A4 COL4A5
25 interstitial nephritis 30.2 ACE ALB UMOD
26 meckel syndrome, type 3 30.2 CEP290 TMEM67
27 hypertension, essential 30.2 ACE ALB COL4A5 CST3 PKD1 PKD2
28 hepatorenal syndrome 30.2 ACE ALB CST3
29 acute kidney tubular necrosis 30.0 ALB CST3 UMOD
30 oligohydramnios 29.7 ACE PKHD1 TMEM67
31 anti-basement membrane glomerulonephritis 29.7 COL4A4 COL4A5
32 encephalocele 29.5 CEP290 TMEM67
33 medullary cystic kidney disease 1 12.6
34 autosomal dominant tubulointerstitial kidney disease 12.6
35 hyperuricemia, pulmonary hypertension, renal failure, and alkalosis syndrome 12.5
36 nephrolithiasis, x-linked recessive, with renal failure 12.5
37 medullary cystic kidney disease 2 12.4
38 autosomal dominant tubulointerstitial kidney disease, umod-related 12.4
39 ventriculomegaly with cystic kidney disease 12.4
40 bifid nose with or without anorectal and renal anomalies 12.4
41 uromodulin-associated kidney disease 12.4
42 autosomal dominant tubulointerstitial kidney disease, muc1-related 12.3
43 iga nephropathy 1 12.3
44 polycystic kidney disease 5 12.3
45 glomerulocystic kidney disease with hyperuricemia and isosthenuria 12.3
46 polycystic kidney disease, infantile severe, with tuberous sclerosis 12.3
47 autoimmune interstitial lung, joint, and kidney disease 12.3
48 iga nephropathy 3 12.3
49 polycystic kidney disease 6 with or without polycystic liver disease 12.3
50 nephropathy with pretibial epidermolysis bullosa and deafness 12.2

Comorbidity relations with Kidney Disease via Phenotypic Disease Network (PDN): (show top 50) (show all 54)


Active Peptic Ulcer Disease Acute Cystitis
Acute Kidney Failure Acute Myocardial Infarction
Alzheimer Disease Aortic Valve Disease 1
Bladder Neck Obstruction Bronchitis
Bronchopneumonia Cardiac Arrest
Cardiogenic Shock Chronic Kidney Failure
Chronic Myocardial Ischemia Decubitus Ulcer
Deficiency Anemia Diabetic Polyneuropathy
Encephalopathy Esophagitis
Familial Atrial Fibrillation First-Degree Atrioventricular Block
Generalized Atherosclerosis Gout
Heart Disease Hydronephrosis
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Intestinal Obstruction
Iron Deficiency Anemia Ischemic Heart Disease
Malignant Essential Hypertension Microvascular Complications of Diabetes 1
Mitral Valve Disease Nephrosclerosis
Paralytic Ileus Peripheral Vascular Disease
Polycystic Kidney Disease Prostate Cancer
Prostatic Hypertrophy Protein-Energy Malnutrition
Pulmonary Hypertension, Primary, 1 Pyelonephritis
Renal Artery Atheroma Renal Artery Disease
Respiratory Failure Schizophreniform Disorder
Sinoatrial Node Disease Swallowing Disorders

Graphical network of the top 20 diseases related to Kidney Disease:



Diseases related to Kidney Disease
Sources

Symptoms & Phenotypes for Kidney Disease

About this section

UMLS symptoms related to Kidney Disease:


polyuria

MGI Mouse Phenotypes related to Kidney Disease:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 9.97 ACE CEP290 COL4A5 CST3 PKD1 PKD1L1
2 digestive/alimentary MP:0005381 9.8 ALB COL4A4 PKD1 PKD1L1 PKD2 PKHD1
3 liver/biliary system MP:0005370 9.7 ACE ALB CEP290 PKD1 PKD2 PKHD1
4 renal/urinary system MP:0005367 9.7 ACE ALB CEP290 COL4A4 COL4A5 PKD1
5 reproductive system MP:0005389 9.23 ACE CEP290 CST3 PKD1 PKD1L1 PKD1L2
Sources

Drugs & Therapeutics for Kidney Disease

About this section

Drugs for Kidney Disease (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 1574)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Perindopril Approved Phase 4,Phase 3 107133-36-8, 82834-16-0 107807
2
Valsartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 137862-53-4 60846
3
Angiotensin II Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 11128-99-7, 68521-88-0, 4474-91-3 172198 65143
4
leucovorin Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 58-05-9 6006 143
5
Pitavastatin Approved Phase 4,Phase 3,Phase 1 147511-69-1, 147526-32-7 5282452 6366718
6
Phytonadione Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 84-80-0 4812 5284607
7
Losartan Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 114798-26-4 3961
8
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 58-93-5 3639
9
Fosinopril Approved Phase 4,Phase 3,Phase 2,Not Applicable 98048-97-6 55891
10
Simvastatin Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 79902-63-9 54454
11
Oxycodone Approved, Illicit, Investigational Phase 4,Phase 3,Not Applicable 76-42-6 5284603
12
Acarbose Approved, Investigational Phase 4,Phase 3,Early Phase 1 56180-94-0 441184
13
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 111025-46-8 4829
14
Acetylcysteine Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 616-91-1 12035
15
Moxonidine Approved, Investigational Phase 4 75438-57-2 4810
16
Prednisolone phosphate Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 302-25-0
17
Methylprednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 83-43-2 6741
18
Prednisolone Approved, Vet_approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 50-24-8 5755
19
Methylprednisolone hemisuccinate Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable 2921-57-5
20
Enalapril Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 75847-73-3 5362032 40466924
21
Enalaprilat Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 76420-72-9 6917719
22
rituximab Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 174722-31-7 10201696
23
Pentoxifylline Approved, Investigational Phase 4,Phase 2,Phase 3,Not Applicable 6493-05-6 4740
24
Irbesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 138402-11-6 3749
25
Telmisartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144701-48-4 65999
26
Candesartan cilexetil Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 145040-37-5 2540
27
Olmesartan Approved, Investigational Phase 4,Phase 3,Phase 2,Not Applicable 144689-63-4, 144689-24-7 158781 130881
28
Ezetimibe Approved Phase 4,Phase 3,Phase 2,Phase 1 163222-33-1 150311
29
Mycophenolic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 24280-93-1 446541
30
Benzocaine Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 94-09-7, 1994-09-7 2337
31 tannic acid Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1
32
Iron Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 7439-89-6 23925
33
Insulin Glargine Approved Phase 4,Phase 3,Not Applicable,Early Phase 1 160337-95-1
34
Insulin Lispro Approved Phase 4,Phase 3,Not Applicable 133107-64-9
35
Exenatide Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 141758-74-9 15991534
36
Spironolactone Approved Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 52-01-7, 1952-01-7 5833
37
Clonidine Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 4205-90-7 2803
38
Furosemide Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1,Not Applicable 54-31-9 3440
39
Doxazosin Approved Phase 4,Phase 3,Not Applicable 74191-85-8 3157
40
Atenolol Approved Phase 4,Phase 3,Phase 1,Phase 2,Early Phase 1 29122-68-7 2249
41
Aspirin Approved, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 50-78-2 2244
42
Ramipril Approved Phase 4,Phase 3,Phase 2,Not Applicable 87333-19-5 5362129
43
Amlodipine Approved Phase 4,Phase 3,Phase 2,Not Applicable,Early Phase 1 88150-42-9 2162
44
Ticlopidine Approved Phase 4,Phase 3,Phase 2,Phase 1 55142-85-3 5472
45
Clopidogrel Approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable 113665-84-2, 120202-66-6 60606
46
Ticagrelor Approved Phase 4,Phase 3,Phase 1,Phase 2 274693-27-5 9871419
47
Zaleplon Approved, Illicit, Investigational Phase 4 151319-34-5 5719
48
Alprostadil Approved, Investigational Phase 4 745-65-3 149351 5280723
49
Miconazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1,Not Applicable,Early Phase 1 22916-47-8 4189
50
Sirolimus Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1,Not Applicable,Early Phase 1 53123-88-9 46835353 6436030 5284616

Interventional clinical trials:

(show top 50) (show all 10000)
# Name Status NCT ID Phase Drugs
1 Effect of Valsartan vs Perindopril on HOMA-IR Index in Patients With Chronic Kidney Disease Unknown status NCT02299310 Phase 4 Valsartan;Perindopril
2 The Effect and Safety of the Seasonal Trivalent Influenza Vaccine in Chronic Kidney Disease Patients Not on Dialysis Unknown status NCT02105519 Phase 4
3 Folic Acid for Prevention of Contrast Induced Nephropathy Unknown status NCT02444013 Phase 4 Folic acid;Placebo
4 Effects of an Exercise Program in Patients With Hypertensive Chronic Kidney Disease Unknown status NCT01155128 Phase 4
5 Efficacy and Safety of Abelmoschus Manihot for Chronic Kidney Disease Unknown status NCT02231138 Phase 4 Abelmoschus manihot (AM)
6 Safety and Efficacy of Shenyankangfu Tablets for Chronic Kidney Disease Unknown status NCT02885857 Phase 4 Shenyan Kangfu Tablet
7 The Prevention of Contrast Induced Nephropathy by Sarpogrelate in Patients With Chronic Kidney Disease Unknown status NCT01165567 Phase 4 sarpogrelate
8 Preventive Effect of Pitavastatin on Contrast-Induced Nephropathy in Patients With Renal Dysfunction Unknown status NCT01871792 Phase 4 Pitavastatin;Placebo
9 Keto-/Amino Acid Supplemented Low Protein Diet in Patients With Chronic Kidney Disease Unknown status NCT00364884 Phase 4 ketoaminoacid
10 Vitamin K2 and Vessel Calcification in Chronic Kidney Disease Patients Unknown status NCT01101698 Phase 4 Vitamin K2+10μg cholecalciferol;Vitamin D
11 Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy Unknown status NCT02231125 Phase 4 Losartan;Abelmoschus manihot
12 Benidipine and Hydrochlorothiazide in Fosinopril Treated Chronic Kidney Disease Patients With Hypertension Unknown status NCT02646397 Phase 4 Fosinopril;Benidipine;Hydrochlorothiazide
13 Efficacy and Safety of Simvast Controlled Release (CR) and Zocor in Chronic Kidney Disease(CKD) Stage 3, 4 and 5 Patients With Hyperlipidemia Unknown status NCT01564875 Phase 4 Simvast CR;Zocor
14 Opioids in Chronic Kidney Disease Patients Undergoing Hemodialysis Unknown status NCT02452437 Phase 4 Oxycodone
15 Thiazolidinedione (TZD) on the Diabetic Retinopathy and Nephropathy Unknown status NCT01175486 Phase 4 Actos (Pioglitazone);Acarbose
16 Effect of Intravenous Acetadote on Incidence of Contrast Induced Nephropathy Unknown status NCT00939913 Phase 4 intravenous NAC;Placebo
17 Sympathetic Nervous System Inhibition for the Treatment of Diabetic Kidney Disease Unknown status NCT01094769 Phase 4 Moxonidine;Placebo
18 Rituximab in Recurrent IgA Nephropathy Unknown status NCT02571842 Phase 4 Intravenous Rituximab;ACEI/ARB and corticosteroids
19 Safety of Add on Aliskiren to Angiotensin Converting Enzyme Inhibitor (ACEI) and Angiotensin I Receptor Blocker (ARB) Treatment in Type 2 Diabetes With Nephropathy Unknown status NCT00949351 Phase 4 Aliskiren 300mg/d
20 N-GAL Allows Intensive Treatment of Contrast Induced Nephropathy Unknown status NCT01491243 Phase 4 Intensive treatment with sodium bicarbonate;Standard treatment with saline infusion
21 Renoprotection by Pentoxifylline and Angiotensin Receptor Blocker in Chronic Kidney Disease (CKD) Unknown status NCT01377285 Phase 4 ARB;Pentoxifylline;Placebo (for Pentoxifylline)
22 Ezetimibe/Simvastatin Combination in Proteinuric Nephropathy Unknown status NCT00861731 Phase 4 simvastatin;EZE/simvastatin;EZE/simvastatin
23 The Canadian Prevention of Renal and Cardiovascular Endpoints Trial Unknown status NCT00231803 Phase 4
24 Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy Unknown status NCT02981212 Phase 4 Mycophenolate Mofetil;ACE inhibitor;Corticosteroid;ARB
25 The Effects of AST-120 on Endothelial Dysfunction in Patients With Chronic Kidney Disease Unknown status NCT01157260 Phase 4 Kremezin
26 Prevention of Contrast Nephropathy During Diagnostic Coronary Angiogram or PCI With Hydratation Based on LEVDP Unknown status NCT00584350 Phase 4
27 Nutritional Therapy to Prevent Progression of Acute Kidney Injury to Chronic Kidney Disease Unknown status NCT02831062 Phase 4
28 Intravenous Iron in Patients With Anemia of Chronic Kidney Disease Unknown status NCT00204256 Phase 4 Iron sucrose
29 Effect of Exenatide on 24h-UAER in Patients With Diabetic Nephropathy Unknown status NCT02690883 Phase 4 Exenatide;Lispro
30 Aldosterone in Diabetic Nephropathy Unknown status NCT00870402 Phase 4 Spironolactone;Placebo
31 Anti-proteinuric Effect of Calcitriol in Non-diabetic Kidney Disease Patients Unknown status NCT01512862 Phase 4 Calcitriol;Placebo
32 Nephropathy In Type 2 Diabetes and Cardio-renal Events Unknown status NCT00535925 Phase 4 current therapy;irbesartan;ramipril;hydrochlorothiazide;furosemide;amlodipine;atenolol;doxazosin;clonidine;insulin;simvastatin;fibrate;erythropoietin;aspirin
33 Prevention of Contrast-Induced Nephropathy in Diabetic Patients With Undergoing Coronary Angiography Unknown status NCT00950079 Phase 4 Sodium bicarbonate;saline
34 Clinical Trial Technology Development for the Validation of Surrogate Prognostic Markers in Patients With Diabetic Nephropathy Unknown status NCT01673204 Phase 4 Calcitriol;Placebo
35 Ferumoxytol Enhanced Magnetic Resonance Angiography in Chronic Kidney Disease Unknown status NCT02997046 Phase 4
36 Ramipril and Clopidogrel in Oxidative Stress, Vascular Inflammation and Endothelial Dysfunction in Type 2 Diabetes and Diabetic Nephropathy Unknown status NCT01743014 Phase 4 Ramipril;Clopidogrel
37 Pure Red Cell Aplasia in Patients With Chronic Kidney Disease and in Use of Epoetin Alfa Unknown status NCT02648126 Phase 4
38 Platelet Resistance With Ticagrelor or Standard-Dose Clopidogrel Among CKD and ACS Patients Unknown status NCT02459288 Phase 4 Clopidogrel first;Ticagrelor first
39 Effect of Arotinolol Hydrochloride on Cardiovascular Events in Hypertensive Haemodialysis Patients Unknown status NCT01351636 Phase 4 Arotinolol Hydrochloride;Non arotinolol group
40 Low Protein Diet Supplemented With Ketoanalogs on Reducing Proteinuria and Maintaining Nutritional Status in Type 2 Diabetic Nephropathy Unknown status NCT01300273 Phase 4
41 Effect of Sarpogrelate On the Nephropathy in Type 2 Diabetes (SONATA Study) Unknown status NCT01869881 Phase 4 Anplag(Sarpogrelate);Placebo
42 COmparison of the Pharmacodynamics and Pharmacokinetics Ticagrelor Versus Clopidogrel in Patients With CKD and NSTE-ACS Unknown status NCT02578537 Phase 4 Ticagrelor;Clopidogrel
43 Efficacy and Safety of Alprostadil Prevent Contrast Induced Nephropathy Unknown status NCT01722513 Phase 4 Alprostadil ﹠control
44 Effect of Vitamin D Supplement on Osteoprotegin Expression and Disease Progression in Patients With Chronic Kidney Disease Stage 1 and 2 Unknown status NCT01561222 Phase 4 Calcitriol;placebo
45 Enhancing Dialysis Adequacy: Effects of Intradialytic Exercise Unknown status NCT01481688 Phase 4
46 The Change of Urinary Angiotensinogen Excretion After Valsartan Treatment in Patients With Persistent Proteinuria Unknown status NCT00858299 Phase 4 valsartan
47 Reduction or Discontinuation of CNI's With Conversion to Everolimus-Based Immunosuppresion Unknown status NCT00443508 Phase 4 adding Certican to therapy;reducing Tacrolimus
48 Impact of Conversion From Tacrolimus to Sirolimus in African American Renal Transplant Recipients Unknown status NCT00999258 Phase 4 sirolimus
49 Pulse Wave Velocity, Pulse Wave Morphology and Blocking of the Reninangiotensin System in Patients With Chronic Kidney Disease Unknown status NCT00235287 Phase 4 Candesartan and enalapril;candesartan and enalapril;candesartan and enalapril;candesartan and enalapril
50 Aliskiren and Muscle Sympathetic Nerve Activity Unknown status NCT00719316 Phase 4 Aliskiren

Search NIH Clinical Center for Kidney Disease

Inferred drug relations via UMLS 73 / NDF-RT 51 :


Cochrane evidence based reviews: kidney diseases

Sources

Genetic Tests for Kidney Disease

About this section

Genetic tests related to Kidney Disease:

# Genetic test Affiliating Genes
1 Abnormality of the Kidney 29
2 Nephropathy 29
Sources

Anatomical Context for Kidney Disease

About this section

MalaCards organs/tissues related to Kidney Disease:

41
Kidney, Bone, Endothelial, Heart, Liver, Testes, Neutrophil

The Foundational Model of Anatomy Ontology organs/tissues related to Kidney Disease:

19
The Kidney
Sources

Publications for Kidney Disease

About this section

Articles related to Kidney Disease:

(show top 50) (show all 8061)
# Title Authors Year
1
Expression of inflammasome complex mRNA and its targeted microRNA in type 2 diabetes mellitus: A possible predictor of the severity of diabetic nephropathy. ( 30151904 )
2019
2
Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease. ( 30203374 )
2019
3
Immunoglobulin A Nephropathy and Immunoglobulin A Vasculitis. ( 30454736 )
2019
4
Analytical validity of a genotyping assay for use with personalized antihypertensive and chronic kidney disease therapy. ( 30489456 )
2019
5
Prenatal MR imaging features of Caroli syndrome in association with autosomal recessive polycystic kidney disease. ( 30510609 )
2019
6
Estimated Glomerular Filtration Rates Show Minor but Significant Differences Between the Single and Subgroup Creatinine-Based Chronic Kidney Disease Epidemiology Collaboration Equations. ( 30430784 )
2019
7
Effector and regulatory B cells in immune-mediated kidney disease. ( 30443016 )
2019
8
Genes and environment in chronic kidney disease hotspots. ( 30451737 )
2019
9
Chronic Kidney Disease and Dietary Measures to Improve Outcomes. ( 30454747 )
2019
10
Growth hormone and chronic kidney disease. ( 30394899 )
2019
11
Protective association between JC polyoma viruria and kidney disease. ( 30320619 )
2019
12
Methylglyoxal stress, the glyoxalase system, and diabetic chronic kidney disease. ( 30320620 )
2019
13
Sex hormones and their influence on chronic kidney disease. ( 30320621 )
2019
14
Mild to moderate chronic kidney disease and functional disability in community-dwelling older adults. The Cardiovascular risk profile in Renal patients of the Italian Health Examination Survey (CARHES) study. ( 30343147 )
2019
15
Racial-ethnic differences in chronic kidney disease-mineral bone disorder in youth on dialysis. ( 30267239 )
2019
16
Obstructive sleep apnea in non-dialyzed chronic kidney disease patients: Association with body adiposity and sarcopenia. ( 30219685 )
2019
17
DDT and its metabolites could contribute to the aetiology of chronic kidney disease of unknown aetiology (CKDu) and more studies are a priority. ( 30227991 )
2019
18
There is no evidence that organochlorine pesticides, such as DDT, cause chronic kidney disease of unknown etiology. ( 30243793 )
2019
19
Exploring the immune response, tolerance and resistance in proliferative kidney disease of salmonids. ( 30248359 )
2019
20
An open-label, single-dose study to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of cinacalcet in pediatric subjects aged 28 days to < 6 years with chronic kidney disease receiving dialysis. ( 30141180 )
2019
21
Comment: Safety and Efficacy of Apixaban Versus Warfarin in Patients With Advanced Chronic Kidney Disease. ( 30187763 )
2019
22
Does a multimethod approach improve identification of medication nonadherence in adolescents with chronic kidney disease? ( 30116892 )
2019
23
Potential target-organ protection of mineralocorticoid receptor antagonist in acute kidney disease. ( 30063639 )
2019
24
Unmet challenges in membranous nephropathy. ( 30451735 )
2019
25
Increased excitatory regulation of the hypothalamic paraventricular nucleus and circulating vasopressin results in the hypertension observed in polycystic kidney disease. ( 30015755 )
2019
26
Pterostilbene, a bioactive component of blueberries, alleviates renal fibrosis in a severe mouse model of hyperuricemic nephropathy. ( 30551434 )
2019
27
Dibenzoylmethane ameliorates lipid-induced inflammation and oxidative injury in diabetic nephropathy. ( 30475214 )
2019
28
Kaempferol attenuates diabetic nephropathy by inhibiting RhoA/Rho-kinase mediated inflammatory signalling. ( 30551415 )
2019
29
Dapagliflozin attenuates early markers of diabetic nephropathy in fructose-streptozotocin-induced diabetes in rats. ( 30551545 )
2019
30
Circular RNA circRNA_15698 aggravates the extracellular matrix of diabetic nephropathy mesangial cells via miR-185/TGF-β1. ( 30054916 )
2019
31
Nine hub genes as the potential indicator for the clinical outcome of diabetic nephropathy. ( 30078220 )
2019
32
Transforming growth factor-β1 in children with diabetic nephropathy. ( 30136104 )
2019
33
DUSP1 recuses diabetic nephropathy via repressing JNK-Mff-mitochondrial fission pathways. ( 30191967 )
2019
34
Haplotypes in vitamin D receptor gene encode risk in diabetic nephropathy. ( 30315926 )
2019
35
Zhen-wu-tang attenuates Adriamycin-induced nephropathy via regulating AQP2 and miR-92b. ( 30551379 )
2019
36
Impact of vascular access on the development of contrast induced nephropathy in patients undergoing coronary angiography and/or percutaneous coronary intervention. ( 30274753 )
2019
37
Serum immunoglobulin G provides early risk prediction in immunoglobulin A nephropathy. ( 30415190 )
2019
38
Dilemmas and challenges in apolipoprotein L1 nephropathy research. ( 30431460 )
2019
39
Effects of additional vasodilatory or nonvasodilatory treatment on renal function, vascular resistance and oxygenation in chronic kidney disease: a randomized clinical trial. ( 29995697 )
2019
40
Atrial fibrillation and stroke risk factors induce decline in creatinine clearance: Is there a specific &amp;quot;fibrillatory kidney disease&amp;quot;? ( 29306477 )
2018
41
Hepcidin and proinflammatory markers inA children with chronic kidney disease: AA case-control studya8c. ( 29451472 )
2018
42
Obesity Paradox in Advanced Kidney Disease: From Bedside to the Bench. ( 29981348 )
2018
43
Endovascular treatment of cerebral aneurysm after renal transplantation in polycystic kidney disease. ( 29444616 )
2018
44
Cinacalcet versus Placebo for secondary hyperparathyroidism in chronic kidney disease patients: a meta-analysis of randomized controlled trials and trial sequential analysis. ( 29449603 )
2018
45
Hydrophobic pore gates regulate ion permeation in polycystic kidney disease 2 and 2L1 channels. ( 29899465 )
2018
46
No evidence for association between APOL1 kidney disease risk alleles and Human African Trypanosomiasis in two Ugandan populations. ( 29470556 )
2018
47
Does Chronic Kidney Disease-Induced Cognitive Impairment Affect Driving Safety? ( 29977582 )
2018
48
IgG4-related kidney disease: the effects of a Rituximab-based immunosuppressive therapy. ( 29765543 )
2018
49
Ift25 is not a cystic kidney disease gene but is required for early steps of kidney development. ( 29626631 )
2018
50
Recommendations for Diagnostic and Prognostic Evaluation of Autosomal Dominant Polycystic Kidney Disease (ADPKD) with a Focus on Imaging. ( 29382260 )
2018